bearish
Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization
591 Views13 Sep 2019 11:27
Shanghai Fosun Pharmaceutical (Group) (2196 HK), the parent company of Shanghai Henlius which in the process of book building today to raise up to...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (21 Sep 2019) - Lendlease Global REIT, Budweiser APAC, Shanghai Henlius Bio21 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China18 Sep 2019
- ECM Weekly (14 Sep 2019) - Budweiser APAC, ESR Cayman, Henlius, AllHome, Topsports14 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap11 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation22 Aug 2019
x